Synthetic peptide allergy vaccine shows efficacy

Recent strong data on an allergy vaccine from a phase 2 study by Oxford-based Circassia provided welcome news to the UKs Imperial Innovations Group, which owns 20% of the company. In the race for a slice of the multi-million-dollar allergy market, Circassia has three other close competitorsWhitehous...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2013-05, Vol.31 (5), p.371-372
Main Author: Osborne, Randy
Format: Article
Language:English
Subjects:
631/250/249/2510/9
631/61/24/590/2030
Agriculture
Allergic reaction
Allergies
Allergy
Animals
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Cats
Clinical Trials, Phase II as Topic
Evidence-Based Medicine
Humans
Hypersensitivity - immunology
Hypersensitivity - therapy
Life Sciences
news
Peptides
Peptides - chemical synthesis
Peptides - immunology
Peptides - therapeutic use
Prevention
Properties
Synthetic vaccines
Treatment Outcome
Vaccines
Vaccines, Synthetic - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent strong data on an allergy vaccine from a phase 2 study by Oxford-based Circassia provided welcome news to the UKs Imperial Innovations Group, which owns 20% of the company. In the race for a slice of the multi-million-dollar allergy market, Circassia has three other close competitorsWhitehouse Station, New Jerseybased Merck; Horsholm, Denmarkbased Lundbeck Foundation subsidiary ARK-Abello; and French biotech Stallergenes located in Paris (Table 1). In contrast to these latter companies, which use natural extracts of whole allergens in their treatments, Circassia has adopteda novel approachusing a mixture ofsynthetic peptides(derived from catallergen epitopes) toinduce tolerance.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0513-371a